Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evenamide - Newron Pharmaceuticals

Next Previous
Search
Drug Profile

Evenamide - Newron Pharmaceuticals

Alternative Names: NW-3509; NW-3509A

Latest Information Update: 15 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Newron Pharmaceuticals
  • Class Antidepressants; Antiepileptic drugs; Antimanics; Antipsychotics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Nav1.3 voltage-gated sodium channel inhibitors; NAV1.7 voltage gated sodium channel expression inhibitors; Nav1.7 voltage-gated sodium channel inhibitors; NAV1.8 voltage gated sodium channel expression inhibitors; Nav1.8 voltage-gated sodium channel inhibitors; Serotonin 5-HT2 receptor agonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Schizophrenia
  • Phase II/III Psychiatric disorders

Most Recent Events

  • 09 Jan 2025 Newron Pharmaceuticals and Myung In Pharm entered into licensing agreement for Evenamide
  • 13 Dec 2024 Evenamide licensed to EA Pharma in Japan and other designated Asian territories (Brunei Darussalam, Cambodia, Indonesia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam)
  • 06 Nov 2024 Newron Pharmaceuticals completes a phase II/III trial in Schizophrenia (Adjunctive treatment) in Estonia, Poland, Hungary, Czech Republic, Italy, Germany (PO) (EudraCT2020-006062-36)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top